Autolus Therapeutics
Autolus Therapeutics
AUTL
NASDAQ
1.86
USD
-1.59%
About
Autolus Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. It is focused on chimeric antigen receptor (CAR)-T cell therapy. Using a suite of proprietary and modular T cell programming technologies, it is engineering targeted, controlled and highly active T cell therapy product candidates that are designed to recognize target cells, break down their defense mechanisms and eliminate these cells.
It has a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. Its products pipeline includes obe-cel (FELIX), obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9.
AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting T Cell Receptor Beta Constant (TRBC) 1 and TRBC 2..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 481.7K |
| Three Month Average Volume | 24.9M |
| High Low | |
| Fifty-Two Week High | 7.45 USD |
| Fifty-Two Week Low | 2.01 USD |
| Fifty-Two Week High Date | 12 Jan 2024 |
| Fifty-Two Week Low Date | 03 Oct 2023 |
| Price and Volume | |
| Current Price | 3.93 USD |
| Beta | 2 |
| Relative Price Change | |
| Four Week Relative Price Change | -17.33% |
| Thirteen Week Relative Price Change | -12.36% |
| Twenty-Six Week Relative Price Change | -42.63% |
| Fifty-Two Week Relative Price Change | -2.30% |
| Year-to-Date Relative Price Change | -48.47% |
| Price Change | |
| One Day Price Change | 3.15% |
| Thirteen Week Price Change | -6.21% |
| Twenty-Six Week Price Change | -36.92% |
| Five Day Price Change | -1.50% |
| Fifty-Two Week Price Change | 22.43% |
| Year-to-Date Price Change | -38.98% |
| Month-to-Date Price Change | -16.20% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | -99999.99 USD |
| Book Value Per Share (Most Recent Quarter) | -99999.99 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | -99999.99 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | -99999.99 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -0.85471 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0.00976 USD |
| Revenue Per Share (Trailing Twelve Months) | 0.05021 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -1.198 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -1.163 USD |
| Normalized (Last Fiscal Year) | -1.18241 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -1.198 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -1.163 USD |
| Including Extraordinary Items (Last Fiscal Year) | -1.198 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -1.163 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | -99999.99 USD |
| Cash Per Share (Most Recent Quarter) | -99999.99 USD |
| Cash Flow Per Share (Last Fiscal Year) | -1.16006 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -1.08613 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -0.76992 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -4,390 |
| Cash Flow Revenue (Trailing Twelve Months) | -1,533 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -2,157.93% |
| Pretax Margin (Last Fiscal Year) | -12,273.38% |
| Pretax Margin (5 Year) | -5,357.88% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -10,583.10% |
| Operating Margin (Trailing Twelve Months) | -1,775.71% |
| Operating Margin (5 Year) | -5,185.32% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -12,272.26% |
| Net Profit Margin (Trailing Twelve Months) | -2,229.04% |
| Net Profit Margin (5 Year) | -5,098.00% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -99,999.99% |
| Tangible Book Value (5 Year) | -13.68% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | 40.22% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -0.33% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -99,999.99% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 16.39% |
| EPS Change (Trailing Twelve Months) | 4.03% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 9 |
| Price to Tangible Book (Most Recent Quarter) | 2 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -705,939,000 |
| Net Debt (Last Fiscal Year) | -239,566,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 616 |
| Price to Sales (Trailing Twelve Months) | 100 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | -100,000 |
| Price to Book (Most Recent Quarter) | -100,000 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 6 |
| Current Ratio (Most Recent Quarter) | 19 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -156,573,000 |
| Free Cash Flow (Trailing Twelve Months) | -160,967,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -6 |
| Net Interest Coverage (Trailing Twelve Months) | -5 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -48.14% |
| Return on Assets (Trailing Twelve Months) | -35.87% |
| Return on Assets (5 Year) | -42.32% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -101.61% |
| Return on Equity (Trailing Twelve Months) | -61.80% |
| Return on Equity (5 Year) | -61.27% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -53.81% |
| Return on Investment (Trailing Twelve Months) | -38.27% |
| Return on Investment (5 Year) | -46.61% |